Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA
Hematology Oncology Consultant, Hematology - Louisiana North Job
Celgene Corporation - Louisiana, LA, US
Associate Director, Global Production Planning & Inventory Control Job
Celgene Corporation - Basking Ridge, NJ, US

More Jobs >>

Events

Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia
Just Released: New Trends in Preventive and Therapeutic Vaccine
Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA

More Events >>

Related Tags >> Vaccine adjuvant

Kineta News

Most Popular Kineta Story

Kineta, UW scientists reap $13M adjuvant grant

November 12, 2009 — 10:07am ET | By John Carroll

Tiny Seattle-based Kineta has reaped $6.8 million of a $13 million grant to fund the development of new adjuvants for vaccines. And the rest of the money will go to Michael Gale Jr. and Michael Read more...

Kineta Press Releases

Kineta Wins New NIH Contract Aimed at Speeding Development of Novel Drug Classes

Latest Headlines

Kineta, UW scientists reap $13M adjuvant grant
November 12, 2009

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK